Literature DB >> 6945294

Prognostic value of chromosomal findings in the blast phase of Ph1-positive chronic myeloid leukaemia (CML).

E Oláh, K Rák.   

Abstract

Twenty-three patients in various cytological subgroups of blast phase of Ph1-positive chronic myeloid leukaemia were investigated cytogenetically The correlation between prognosis and the cytological and cytogenetic features of blast cells was studied. The best prognosis was found in the myeloid group, followed by the lymphoid, myelomonocytic, megakaryoblastic and finally the promyelocytic groups, in this order. As regards the prognostic significance of the cytogenetic finding, the survival seemed to be the longest among patients with mosaic karyotypes i.e. when further aberrations occurred in some Ph1-positive cells. The course of the disease was the most favourable in the presence of i(17q), especially in patients whose cells had i(17q) as the only aberration. The most severe course of the disease could be found in patients with +8 and/or two Ph1. The results demonstrate the usefulness of chromosome investigations in distinguishing the different cytogenetic subgroups in terminal stages of CML, which also differ prognostically from each other.

Entities:  

Mesh:

Year:  1981        PMID: 6945294     DOI: 10.1002/ijc.2910270306

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  3 in total

1.  Megakaryoblastic micromegakaryocytic crisis in chronic myeloid leukemia.

Authors:  G Lingg; F Schmalzl; J Breton-Gorius; A Tabilio; H E Schaefer; D Geissler; M Schweiger; W Kirchmair
Journal:  Blut       Date:  1985-10

2.  Cytogenetic heterogeneity in blast crisis (BC) of chronic myelogenous leukemia (CML).

Authors:  J Abramson; R S Verma; J Schwartz
Journal:  Blut       Date:  1985-11

3.  Investigations on karyotype evolution in patients with chronic myeloid leukemia (CML).

Authors:  O A Haas; J D Schwarzmeier; E Nacheva; P Fischer; E Paietta
Journal:  Blut       Date:  1984-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.